Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
Vít Procházka,
David Belada,
Andrea Janíková,
Kateřina Benešová,
Heidi Mociková,
Juraj Ďuraš,
Jan Pirnos,
Kateřina Kopečková,
Vít Campr,
Tomáš Fürst,
Robert Pytlík,
Alice Sýkorová,
Jozef Michalka,
Jitka Dlouhá,
Tomáš Papajík,
Marek Trněný
Affiliations
Vít Procházka
Department of Hemato‐Oncology, Faculty of Medicine and Dentistry University Hospital in Olomouc Olomouc Czech Republic
David Belada
Fourth Department of Internal Medicine – Hematology University Hospital Hradec Králové Czech Republic
Andrea Janíková
Department of Hematology and Oncology Masaryk University Hospital Brno Brno Czech Republic
Kateřina Benešová
First Department of Internal Medicine – Hematology First Faculty of Medicine and General Teaching Hospital Prague Czech Republic
Heidi Mociková
Department of Internal Medicine and Hematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine Charles University Prague Czech Republic
Juraj Ďuraš
Department of Hemato‐Oncology University Hospital Ostrava Ostrava Czech Republic
Jan Pirnos
Department of Oncology Hospital České Budějovice České Budějovice Czech Republic
Kateřina Kopečková
Department of Oncology University Hospital Motol Prague Czech Republic
Vít Campr
Department of Pathology and Molecular Medicine University Hospital in Motol Prague Czech Republic
Tomáš Fürst
Department of Mathematical Analysis and Applications of Mathematics, Faculty of Science Palacký University Olomouc Czech Republic
Robert Pytlík
First Department of Internal Medicine – Hematology First Faculty of Medicine and General Teaching Hospital Prague Czech Republic
Alice Sýkorová
Fourth Department of Internal Medicine – Hematology University Hospital Hradec Králové Czech Republic
Jozef Michalka
Department of Hematology and Oncology Masaryk University Hospital Brno Brno Czech Republic
Jitka Dlouhá
First Department of Internal Medicine – Hematology First Faculty of Medicine and General Teaching Hospital Prague Czech Republic
Tomáš Papajík
Department of Hemato‐Oncology, Faculty of Medicine and Dentistry University Hospital in Olomouc Olomouc Czech Republic
Marek Trněný
First Department of Internal Medicine – Hematology First Faculty of Medicine and General Teaching Hospital Prague Czech Republic
Abstract Twenty percent of patients with high‐tumor‐burden (HTB) follicular lymphoma (FL) develop progression/relapse of disease (POD) within 24 months of frontline immunochemotherapy. Unfortunately, about 50% of these patients die within 5 years since POD event. Rituximab maintenance was proven to reduce relapse rate in responding FL, but its role on preventing POD was not defined. We analyzed 1360 HTB‐FL patients from the Czech Lymphoma Study Group registry treated with frontline rituximab‐containing regimen. Of those, 950 cases received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) and achieved complete or partial remission: 712 patients received rituximab maintenance (MAINT) and 238 were a historical observational cohort (OBS). We have proposed a modified POD24 (mPOD24) endpoint for the chemosensitive patients calculated from the end‐of‐induction (EOI). Survival rates since EOI were as follows: 5‐year overall survival (OS) 86.2% versus 94.5% in the OBS and MAINT groups, respectively (P < .001) and 5‐year progression‐free survival 58.5% (OBS) and 75.4% (MAINT) (P < .001). The Cox proportional hazards model showed a decrease in mPOD24 incidence in the MAINT group with the overall hazard rate reduced by 56% (hazard ratio = 0.44; P < .001). The cumulative incidence of mPOD24 was reduced from 24.1% in OBS to 10.1% in MAINT (P < .001). Comparison of non‐mPOD24 cases showed OS similar to that in the general population. Rituximab maintenance given after R‐CHOP resulted in a 2.4‐fold reduction in mPOD24 incidence. Once the non‐POD24 status is achieved, FL does not shorten the patients’ life expectancy.